The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

President Donald Trump rescinded an executive order issued by former President Joe Biden aimed at finding new models for ...

The FDA has extended the review period for the New Drug Application for elamipretide for the treatment of Barth syndrome.

PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...

A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe ...

Milestone Pharmaceuticals (MIST) provided a corporate update and outlined its strategic priorities for 2025. CARDAMYST for Paroxysmal ...

The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.

The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to ...

Sometime in the future, as you are watching your favorite television show or sporting event, amongst the DTC ads featuring ...

The PBM system intentionally blocks lower-cost, FDA-approved biosimilars from being available to patients. Biosimilars are the commonsense, bipartisan solution to out-of-control prescription drug ...